Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Pathos logo — AI-enabled drug development built for patients

Pathos

AI-enabled drug development built for patients

Founded 2022 United States Chicago, United States 96 employees Series D Total: $365.00M

General Information

Company Name Pathos
Founded Year 2022
Location United States Chicago, United States
Employees 96
Funding Stage Series D
Business Model B2B, Platform, SaaS
Revenue Model Licensing, Service Fee, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with Pathos. To contact Pathos, visit pathos.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Pathos compare?

A PDF of Pathos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Pathos soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Pathos

Pathos, founded in 2022 and headquartered in the United States, is a clinical-stage, AI-enabled precision oncology biotech. Its slogan, "AI-enabled drug development built for patients", encapsulates its mission to revolutionize the biopharma sector.

The company is pioneering the integration of AI with multimodal patient data to innovate drug development processes. Utilizing the largest Multimodal Foundation Model in Oncology, Pathos operates an advanced engine that aligns model-driven hypotheses with biological validation and biomarker-centric clinical execution. This strategy aims to expedite the delivery of targeted therapies to patients, significantly improving patient outcomes.

In a noteworthy achievement, Pathos secured a substantial $283.00 million in Series D investment on 01 May 2025. This infusion of capital underlines investor confidence in its cutting-edge approach to oncological therapies. The company's innovative blend of technology and biology positions it as a promising leader in the future of drug development.

Business keywords: AI-enabled Drug Development, Precision Oncology, Multimodal Patient Data, Oncology, Biomarker-driven Clinical Execution, Clinical Trials, Drug Discovery, Cancer Biology, Computational Biology, Biopharma, Model-driven Hypotheses, Precision Medicine

Services & Products

AI-driven Clinical Trials
Precision Therapy Discovery
Data Modeling for Oncology
Biopharmaceutical Collaboration

Target Customers

Biopharmaceutical Companies Clinical Researchers Healthcare Providers Investors in Biotech

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $283.00M -
01 May 2025
Series C $62.00M 4
Builders VC Lightbank Revolution
Builders VC, Lightbank +2
01 Oct 2024
Late VC $20.00M -
01 Mar 2023

Pathos Alternatives & Competitors

View All Alternatives
Pathos vs
Avenzo Therapeutics
Avenzo Therapeutics United States

Developing the next generation of oncology therapies for patients

61 employees
Biotechnology, Health Care
Pathos vs
Frontier Medicines
Frontier Medicines United States

Frontier Medicines is a biopharmaceutical company that “drugs the undruggable” to transform patients...

Series C
81 employees
Biopharma, Biotechnology
Pathos vs
Synnovation Therapeutics
Synnovation Therapeutics United States

A precision oncology company focused on small molecule therapies optimized to target key driver mech...

Series A
52 employees
Biotechnology, Health Care
Also compare with: Pathos vs Regor Therapeutics Group Regor Therapeutics Group View all alternatives

FAQ About Pathos

AI-enabled drug development built for patients
Pathos was founded in 2022.
Pathos is headquartered in Chicago, United States.
Pathos has a B2B, Platform and SaaS business model. Its revenue comes from Licensing, Service Fee and Data Monetization.
Pathos has approximately 96 employees.
Pathos has completed 3 funding rounds, raising a total of $365.00M. The latest funding stage is Series D.
Pathos offers: AI-driven Clinical Trials, Precision Therapy Discovery, Data Modeling for Oncology, Biopharmaceutical Collaboration.
Top alternatives and competitors to Pathos include Avenzo Therapeutics, Frontier Medicines, Synnovation Therapeutics, Exelixis, Regor Therapeutics Group. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Pathos and Avenzo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Pathos, https://bouncewatch.com/company/pathos, updated 15 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes